| Bioactivity | Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease. | ||||||||||||
| Invitro | Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels[1]. | ||||||||||||
| Name | Lusutrombopag | ||||||||||||
| CAS | 1110766-97-6 | ||||||||||||
| Formula | C29H32Cl2N2O5S | ||||||||||||
| Molar Mass | 591.55 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kim ES, et al. Lusutrombopag: First Global Approval. Drugs. 2016 Jan;76(1):155-8. |
Lusutrombopag
CAS: 1110766-97-6 F: C29H32Cl2N2O5S W: 591.55
Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disea
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.